Control Bionics bounces toward record revenue in FY25

Control Bionics is on track for record revenue in FY25 driven by strong performance in the US and growth in Australia.

Control Bionics bounces ahead as it executes a strategy to diversify revenue streams. Pic: Getty.

• Control Bionics (ASX:CBL) on track for record revenue in FY25 with US sales growth accelerating

• Commercialisation of its new NeuroStrip wearable tech progressing across sports science, stroke rehab and diagnostics, with trials underway in the US, Japan and Australia.

• NeuroBounce, its athlete performance program powered by EMG biofeedback, shows strong results in both the US and Australia — with further rollout planned.

Special Report: Medtech Control Bionics is on track for a record year with YTD unaudited revenue to May 31 up 14% to $5.4 million on the same time last year.

Control Bionics (ASX:CBL)said growth had been driven by strong performance in the US and growth in Australia.

In the US revenue growth has been bolstered by the benefits of a new Healthcare Common Procedure Coding System (HCPCS) insurance code, improving reimbursement processes and accelerated market adoption.

In Australia, more consistent approvals from the National Disability Insurance Scheme (NDIS) have underpinned a strong year for revenue growth, with improved reliability in funding translating to greater client access and commercial momentum.

Watch: Control Bionics 2025

Growing demand, traction in new commercial markets

Control Bionics said the positive upward trend reflected growing demand for its flagship NeuroNode surface electromyography (‘EMG’) device and increasing traction in new commercial markets, including the NeuroNode-only sales strategy and early-stage adoption of NeuroStrip.

NeuroNode is a wearable, watch-like, wireless non-invasive EMG and spatial sensor device to assist cognitive people with physical disabilities perform everyday functions, including sufferers of cerebral palsy or motor neuron disease (MND).

The NeuroNode-only sales strategy is Control Bionics’ focused approach to selling the assistive technology device as a standalone product, rather than bundling it with other components like tablets or eye gaze systems.

The strategy aims to simplify the sales process, enhance accessibility and expand market reach by offering the NeuroNode independently.

Control Bionics’ miniaturised wearable EMG device NeuroStrip expands the company’s market from disabilities to sports science, occupational health and rehabilitation sectors.

NeuroStrip measures physiological data such as unintentional muscle movements with a new software version launched Including user logins and AWS cloud-based data storage, enabling software monetisation as a SaaS product.

NeuroBounce scores traction, bouncing ahead in Australia

Control Bionics said its NeuroBounce program continued to gain commercial traction as a compelling application of its EMG technology in the sports performance market.

Using NeuroStrip’s EMG technology, the program aims to ensure athletes unlock new muscle fibres to deliver increased explosiveness.

In the US the program has delivered measurable performance improvements for athletes across multiple sports.

The company has also successfully completed the first NeuroBounce program in Australia with five high-performance basketballers from SEDA College in Melbourne.

Results from the four-week program include:

• All athletes increased their vertical jump height by at least 5cm;
• One athlete achieved an extraordinary 14cm increase in vertical jump height; and
• Sprint test pace improved materially across the group.

The company is in discussions with additional sports organisations and performance centres in Australia and the US as it looks to scale the NeuroBounce program further in FY26.

Focused on diversifying revenues in FY26

Control Bionics remains focused on executing its strategy to diversify revenues beyond assistive communication into high-growth areas such as sports performance, rehabilitation and health diagnostics.

The latest version of the NeuroStrip hardware weighs less than a sheet of paper and is being trialled across the US, Australia and Japan.

Control Bionics said seamlessly integrates with its updated mobile app supporting instant data review, data labelling, usage logging, and real-time analytics – key features to support rollout as a SaaS product.

The company said the enhancements were expected to unlock new recurring revenue streams and provide valuable insight into product usage and performance.

“We are very encouraged by the trajectory of our global business,” CEO Jeremy Steele said.

“FY25 is shaping up to be our best year yet in terms of sales revenue, which is a testament to our expanding market presence and continued focus on commercial execution.

“With solid momentum heading into June, we remain confident in the underlying strength of our diversified strategy.”

This article was developed in collaboration with Control Bionics,  a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Originally published as Control Bionics bounces toward record revenue in FY25